Type 2 diabetes is associated with obesity, insulin resistance of adipose tissue, muscle and liver, excessive deposition of fat in non-adipose tissues, reduced liver, skeletal muscle glycogen synthesis, etc. We examined the effect of 1,4-dihydropyridine derivative cerebrocrast, a new antidiabetic agent, on the changes of glucose and lipid profiles in   the blood, also glycogen, triacylglycerol, and cholesterol levels in the kidney, heart and liver. Fatty acid oxidation in the liver mitochondria, ketone body production, and body, kidney, heart and liver weight of normal rats after triple administration of the compound were also checked. Cerebrocrast at doses of 0.05 and 0.5 mg kg^-1 body weight (p.o) significantly increased glycogen content in the liver, decreased blood glucose and glycogen level in the kidney and heart. It partially inhibited fatty acid b-oxidation in the liver mitochondria, and therefore favoured glucose oxidation and prevented the accumulation of lactate in the cells. Cerebrocrast promoted lipolysis and decreased body weight. Cerebrocrast decreased blood levels of b-hydroxybutyrate, it may be used as an energy source in the brain. It did not increase liver, kidney, and heart mass. Cerebrocrast increased cholesterol in the liver and heart that can be used for plasma membrane formation at differentiation and proliferation of cells, as well as for synthesis of steroid hormones in the adrenal gland.